CARA Cara Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CARA

Price (delayed)

$0.7071

Market cap

$38.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.19

Enterprise value

$29.63M

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is ...

Highlights
CARA's gross profit has plunged by 57% YoY but it is up by 9% from the previous quarter
The quick ratio has declined by 36% year-on-year but it has increased by 11% since the previous quarter
Cara Therapeutics's equity has plunged by 64% YoY and by 33% from the previous quarter
The revenue has declined by 50% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.caratherapeutics.com
Peers: TRVN JNJ CPIX PFE

Key stats

What are the main financial stats of CARA
Market
Shares outstanding
54.66M
Market cap
$38.65M
Enterprise value
$29.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
1.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.41
Earnings
Revenue
$20.97M
EBIT
-$117.91M
EBITDA
-$115.58M
Free cash flow
-$94.45M
Per share
EPS
-$2.19
Free cash flow per share
-$1.74
Book value per share
$1.05
Revenue per share
$0.39
TBVPS
$2.32
Balance sheet
Total assets
$125.84M
Total liabilities
$68.76M
Debt
$43.17M
Equity
$57.09M
Working capital
$90.57M
Liquidity
Debt to equity
0.76
Current ratio
4.54
Quick ratio
4.08
Net debt/EBITDA
0.08
Margins
EBITDA margin
-551.2%
Gross margin
70.6%
Net margin
-565.2%
Operating margin
-579.4%
Efficiency
Return on assets
-89.6%
Return on equity
-122.1%
Return on invested capital
-175.2%
Return on capital employed
-117.6%
Return on sales
-562.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CARA stock price

How has the Cara Therapeutics stock price performed over time
Intraday
-3.14%
1 week
-0.27%
1 month
-19.95%
1 year
-82.75%
YTD
-4.83%
QTD
-22.3%

Financial performance

How have Cara Therapeutics's revenue and profit performed over time
Revenue
$20.97M
Gross profit
$14.79M
Operating income
-$121.5M
Net income
-$118.51M
Gross margin
70.6%
Net margin
-565.2%
CARA's net margin has dropped by 177% year-on-year and by 3% since the previous quarter
Cara Therapeutics's operating margin has plunged by 177% YoY and by 2.3% from the previous quarter
CARA's gross profit has plunged by 57% YoY but it is up by 9% from the previous quarter
The revenue has declined by 50% year-on-year

Growth

What is Cara Therapeutics's growth rate over time

Valuation

What is Cara Therapeutics stock price valuation
P/E
N/A
P/B
0.67
P/S
1.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.41
Cara Therapeutics's EPS has decreased by 38% YoY
The P/B is 81% lower than the 5-year quarterly average of 3.5 and 48% lower than the last 4 quarters average of 1.3
Cara Therapeutics's equity has plunged by 64% YoY and by 33% from the previous quarter
CARA's P/S is 89% below its 5-year quarterly average of 17.3 and 59% below its last 4 quarters average of 4.5
The revenue has declined by 50% year-on-year

Efficiency

How efficient is Cara Therapeutics business performance
Cara Therapeutics's ROS has plunged by 175% YoY and by 2.4% from the previous quarter
Cara Therapeutics's return on equity has shrunk by 168% YoY and by 28% QoQ
CARA's ROA has shrunk by 122% YoY and by 13% QoQ
CARA's return on invested capital is down by 3.2% since the previous quarter

Dividends

What is CARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CARA.

Financial health

How did Cara Therapeutics financials performed over time
The total assets is 83% more than the total liabilities
Cara Therapeutics's total liabilities has soared by 193% YoY and by 132% from the previous quarter
Cara Therapeutics's current ratio has decreased by 37% YoY but it has increased by 3.2% from the previous quarter
CARA's debt is 24% smaller than its equity
Cara Therapeutics's equity has plunged by 64% YoY and by 33% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.